What is a stock summary page? Click here for an overview.
Business Description
TSH Biopharm Corp Ltd
NAICS : 325412
SIC : 2834
ISIN : TW0008432006
Description
TSH Biopharm Corp Ltd is engaged in the sale of a variety of pharmaceuticals, chemical drugs and biotechnology services. The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.28 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Interest Coverage | 374.16 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 7.75 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 39 | |||||
| 3-Year EBITDA Growth Rate | 41.4 | |||||
| 3-Year EPS without NRI Growth Rate | 34 | |||||
| 3-Year FCF Growth Rate | 38.2 | |||||
| 3-Year Book Growth Rate | 8.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.02 | |||||
| 9-Day RSI | 23.65 | |||||
| 14-Day RSI | 29.83 | |||||
| 3-1 Month Momentum % | -6.07 | |||||
| 6-1 Month Momentum % | -2.88 | |||||
| 12-1 Month Momentum % | -2.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.25 | |||||
| Quick Ratio | 5.4 | |||||
| Cash Ratio | 4.3 | |||||
| Days Inventory | 105.55 | |||||
| Days Sales Outstanding | 67.53 | |||||
| Days Payable | 43.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.3 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| 3-Year Dividend Growth Rate | -10.7 | |||||
| Forward Dividend Yield % | 2.3 | |||||
| 5-Year Yield-on-Cost % | 1.82 | |||||
| Shareholder Yield % | 1.53 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.23 | |||||
| Operating Margin % | 15.29 | |||||
| Net Margin % | 10.14 | |||||
| FCF Margin % | 16.23 | |||||
| ROE % | 8.72 | |||||
| ROA % | 6.71 | |||||
| ROIC % | 19.68 | |||||
| 3-Year ROIIC % | 21.78 | |||||
| ROC (Joel Greenblatt) % | 70.81 | |||||
| ROCE % | 11.62 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.01 | |||||
| PE Ratio without NRI | 18.95 | |||||
| Shiller PE Ratio | 23.01 | |||||
| Price-to-Owner-Earnings | 16.32 | |||||
| PEG Ratio | 1.71 | |||||
| PS Ratio | 1.93 | |||||
| PB Ratio | 1.54 | |||||
| Price-to-Tangible-Book | 1.94 | |||||
| Price-to-Free-Cash-Flow | 11.85 | |||||
| Price-to-Operating-Cash-Flow | 11.67 | |||||
| EV-to-EBIT | 8.68 | |||||
| EV-to-EBITDA | 7.44 | |||||
| EV-to-Revenue | 1.35 | |||||
| EV-to-FCF | 8.34 | |||||
| Price-to-GF-Value | 0.71 | |||||
| Price-to-Projected-FCF | 1.03 | |||||
| Price-to-Median-PS-Value | 0.39 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.51 | |||||
| Price-to-Graham-Number | 1.28 | |||||
| Price-to-Net-Current-Asset-Value | 2.5 | |||||
| Price-to-Net-Cash | 4.79 | |||||
| Earnings Yield (Greenblatt) % | 11.52 | |||||
| FCF Yield % | 8.46 | |||||
| Forward Rate of Return (Yacktman) % | 15.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TSH Biopharm Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,115.716 | ||
| EPS (TTM) (NT$) | 2.93 | ||
| Beta | 0.12 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.6 | ||
| Volatility % | 35.68 | ||
| 14-Day RSI | 29.83 | ||
| 14-Day ATR (NT$) | 0.910641 | ||
| 20-Day SMA (NT$) | 57.445 | ||
| 12-1 Month Momentum % | -2.05 | ||
| 52-Week Range (NT$) | 53.6 - 71.1 | ||
| Shares Outstanding (Mil) | 38.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TSH Biopharm Corp Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TSH Biopharm Corp Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TSH Biopharm Corp Ltd Frequently Asked Questions
What is TSH Biopharm Corp Ltd(ROCO:8432)'s stock price today?
The current price of ROCO:8432 is NT$55.70. The 52 week high of ROCO:8432 is NT$71.10 and 52 week low is NT$53.60.
When is next earnings date of TSH Biopharm Corp Ltd(ROCO:8432)?
The next earnings date of TSH Biopharm Corp Ltd(ROCO:8432) is .
Does TSH Biopharm Corp Ltd(ROCO:8432) pay dividends? If so, how much?
The Dividend Yield %  of TSH Biopharm Corp Ltd(ROCO:8432) is 2.3% (As of Today), Highest Dividend Payout Ratio of TSH Biopharm Corp Ltd(ROCO:8432) was 1.83. The lowest was 0.43. And the median was 0.97. The  Forward Dividend Yield % of TSH Biopharm Corp Ltd(ROCO:8432) is 2.3%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers